
Histiocytic sarcoma (HS) is a rare hematopoietic malignancy originating from the monocyte/macrophage bone marrow lineage. HS can occur in isolation or in association with other hematological neoplasms such as non-Hodgkin lymphoma (NHL), myelodysplasia, or acute leukemia. Clinically, HS can affect lymph nodes, gastrointestinal tract, skin, bone marrow, and spleen as well as the central nervous system. Most cases of HS follow an aggressive clinical course, with most patients dying of progressive disease within one year of diagnosis.
Male, Lymphoma, Non-Hodgkin, Biopsy, Needle, Prognosis, Immunohistochemistry, Risk Assessment, Diagnosis, Differential, Rare Diseases, Bone Marrow, Myelodysplastic Syndromes, Humans, Female, Histiocytic Sarcoma, Lymph Nodes, Tomography, X-Ray Computed
Male, Lymphoma, Non-Hodgkin, Biopsy, Needle, Prognosis, Immunohistochemistry, Risk Assessment, Diagnosis, Differential, Rare Diseases, Bone Marrow, Myelodysplastic Syndromes, Humans, Female, Histiocytic Sarcoma, Lymph Nodes, Tomography, X-Ray Computed
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
